RedHill Biopharma Ltd. (RDHL)
| Market Cap | 327.97M |
| Revenue (ttm) | 83.88M |
| Net Income (ttm) | -81.88M |
| Shares Out | 46.72M |
| EPS (ttm) | -2.14 |
| PE Ratio | n/a |
| Forward PE | 1,428.57 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 24 |
| Last Price | $7.01 |
| Previous Close | $7.02 |
| Change ($) | -0.01 |
| Change (%) | -0.14% |
| Day's Open | 7.03 |
| Day's Range | 6.99 - 7.14 |
| Day's Volume | 98,835 |
| 52-Week Range | 5.91 - 11.52 |
TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced presentation of...
Coronavirus players may deliver strong returns well into the future.
TEL AVIV, Israel and RALEIGH, N.C., June 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, NC, June 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has comp...
RedHill Biopharma Ltd (NASDAQ:RDHL) has reported its financial results and operational highlights for the first quarter ended March 31, 2021, with the company highlighting a strong end to the first quar...
Redhill Biopharma Ltd. (RDHL) saw its shares surge in the last session with trading volume being higher than average.
Shares of Redhill Biopharma (NASDAQ:RDHL) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share were flat 0.00% year over year to ($0.05), which beat the estimate of...
TEL AVIV, Israel and RALEIGH, N.C., May 27, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (NASDAQ:RDHL) has announced the receipt of two Notices of Allowance from the US Patent and Trademark Office (USPTO) covering opaganib and RHB-107 (upamostat), as methods for the t...
Redhill Biopharma (NASDAQ:RDHL) releases its next round of earnings this Thursday, May 27. Get the latest predictions in Benzinga's essential guide to the company's Q1 earnings report.
TEL AVIV, Israel and RALEIGH, NC, May 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced receipt of two N...
Photo by Elsa Olofsson on Unsplash World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus recently said the COVID-19 pandemic's second year was on track to be its deadliest.
TEL AVIV, Israel and RALEIGH, N.C., May 24, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., May 21, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., May 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
They're approaching the treatment-race finish line.
TEL AVIV, Israel and RALEIGH, N.C., April 9, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (NASDAQ:RDHL) has announced a resolution to patent litigation in the US in response to a generic version of Movantik (naloxegol) which the company acquired the global rights to, e...
TEL AVIV, Israel and RALEIGH, N.C., March 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (NASDAQ:RDHL) announced that it has acted on a request to provide its opaganib treatment on an outpatient basis under compassionate use exemption for several Swiss patients suffer...
TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.
RedHill Biopharma Ltd (NASDAQ: RDHL) has reported FY2020 net revenue of approximately $64 million and gross profit of $27.5 million thanks to the commercialization of its Movantik and Talicia gastrointe...
Shares of Redhill Biopharma (NASDAQ:RDHL) rose 0.9% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 333.33% year over year to ($0.07), which b...
TEL AVIV, Israel and RALEIGH, N.C., March 18, 2021 /PRNewswire/ -- Financials: Full year 2020 net revenues of approximately $64 million, with gross profit of approximately $27.5 million Solid cash balan...
Redhill Biopharma (NASDAQ:RDHL) announces its next round of earnings this Thursday, March 18. Here is Benzinga's everything-that-matters guide for this Thursday's Q4 earnings announcement.
TEL AVIV, Israel and RALEIGH, NC, March 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will r...
TEL AVIV, Israel and RALEIGH, NC, March 5, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will pr...
TEL AVIV, Israel and RALEIGH, N.C., March 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing o...
TEL AVIV, Israel and RALEIGH, NC, March 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to dem...
TEL AVIV, Israel and RALEIGH, N.C., March 1, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has e...
Following the FDA review of data from the U.S. Phase 2 study of opaganib and receipt of its recommendations, RedHill Biopharma Ltd (NASDAQ: RDHL) plans to expand its global Phase 2/3 study of opaganib i...
TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plans to ex...
RedHill (RDHL) doses first patient in phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced agreements with Cosmo Pharmaceuticals NV to manufacture RedHill's largest selling product in the U.S., Movantik, and RHB-204, currently in a Phase 3 U....
TEL AVIV, Israel and RALEIGH, N.C., Feb. 18, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced agreements wi...
RedHill Biopharma Ltd (NASDAQ:RDHL) announced Wednesday that the first patient was dosed in its US Phase 2/3 study of orally-administered RHB-107 (upamostat), an investigational new drug for patients wi...
Are you a high-risk stock picker or cautious investor? No matter your answer, there's a stock for you on this list.
TEL AVIV, Israel and RALEIGH, N.C., Jan. 29, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the inde...
This could be a key year for these companies' treatment candidates.
TEL AVIV, Israel and RALEIGH, N.C., Jan. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing o...
The drugmaker more than doubled the size of its planned public stock offering.
TEL AVIV, Israel and RALEIGH, N.C., Jan. 12, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to d...
TEL AVIV, Israel and RALEIGH, N.C., Jan. 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has e...
RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.
RedHill's (RDHL) opaganib achieves greater improvement in reducing oxygen requirement compared to placebo in a phase II study evaluating it in patients hospitalized with COVID-19 pneumonia.
TEL AVIV, Israel and RALEIGH, N.C., Dec. 31, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that prelimin...
Investors need to pay close attention to RedHill Biopharma (RDHL) stock based on the movements in the options market lately.
RedHill has a stable line of approved, marketed and pipeline products. Its cash balance is a little low.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F fi...
RedHill (RDHL) expands its manufacturing capacity to support the potential emergency use applications to be filed for opaganib to address severe COVID-19 pneumonia in the United States.
About RDHL
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infectio... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | Founded 2009 |
| CEO Dror Ben-Asher | Employees 182 |
| Stock Exchange NASDAQ | Ticker Symbol RDHL |
Financial Performance
In 2020, RDHL's revenue was $64.36 million, an increase of 923.03% compared to the previous year's $6.29 million. Losses were -$76.17 million, 80.1% more than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for RDHL stock is "Strong Buy." The 12-month stock price forecast is 20.43, which is an increase of 191.44% from the latest price.